InsiderTrades

Form 4 for VIR Vir Biotechnology, Inc.

Accepted 2022-02-24 00:00:00 ET · period of report 2022-02-22 · accession 0001209191-22-012952 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-02-24 2022-02-22 VIR Virgin Herbert EVP, CSO, Research M - OptEx $1.53 +1,375 176.8K +0.8% +$2,104
D 2022-02-24 2022-02-22 VIR Virgin Herbert EVP, CSO, Research S - Sale+OE $30.00 -1,375 175.4K -0.8% -$41.2K
D 2022-02-24 2022-02-22 VIR Virgin Herbert EVP, CSO, Research A - Grant $0.00 +70.0K 175.4K +66% $0
D 2022-02-24 2022-02-22 VIR Virgin Herbert EVP, CSO, Research M - OptEx $0.00 -1,375 219.5K -0.6% $0
D 2022-02-24 2022-02-22 VIR Virgin Herbert EVP, CSO, Research A - Grant $0.00 +70.0K 70.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-02-22 M A 1,375 $1.53 176,782 D — —
2 Common Common Stock 2022-02-22 S D 1,375 $30.00 175,407 D — —
3 Common Common Stock 2022-02-22 A A 70,000 $0.00 175,407 D — —
4 Derivative Stock Option (Right to Buy) 2022-02-22 M D 1,375 $0.00 219,505 D $1.53 · — to 2028-01-26 1,375 Common Stock (F3) The option is fully vested and exercisable.
5 Derivative Stock Option (Right to Buy) 2022-02-22 A A 70,000 $0.00 70,000 D $29.48 · — to 2032-02-21 70,000 Common Stock (F4) 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.